SARS-CoV-2-specific ELISA development

被引：68

作者：

Roy, Vicky ^{[1
]}

Fischinger, Stephanie ^{[1
]}

Atyeo, Caroline ^{[1
]}

Slein, Matthew ^{[1
]}

Loos, Carolin ^{[1
,5
]}

Balazs, Alejandro ^{[1
]}

Luedemann, Corinne ^{[1
]}

Astudillo, Michael Gerino ^{[2
]}

Yang, Diane ^{[2
]}

Wesemann, Duane R. ^{[3
]}

Charles, Richelle ^{[4
]}

Lafrate, A. John ^{[2
]}

Feldman, Jared ^{[1
]}

Hauser, Blake ^{[1
]}

Caradonna, Tim ^{[1
]}

Miller, Tyler E. ^{[2
]}

Murali, Mandakolathur R. ^{[2
]}

Baden, Lindsey ^{[3
]}

Nilles, Eric ^{[3
]}

Ryan, Edward ^{[4
]}

Lauffenburger, Douglas ^{[5
]}

Beltran, Wilfredo Garcia ^{[1
,2
]}

Alter, Galit ^{[1
]}

机构：

[1] MIT & Harvard, Ragon Inst MGH, Cambridge, MA 02139 USA

[2] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA

[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[4] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA

[5] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA

来源：

JOURNAL OF IMMUNOLOGICAL METHODS | 2020年 / 484卷

关键词：

CORONAVIRUS;

D O I：

10.1016/j.jim.2020.112832

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Critical to managing the spread of COVID-19 is the ability to diagnose infection and define the acquired immune response across the population. While genomic tests for the novel Several Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) detect the presence of viral RNA for a limited time frame, when the virus is shed in the upper respiratory tract, tests able to define exposure and infection beyond this short window of detectable viral replication are urgently needed. Following infection, antibodies are generated within days, providing a durable read-out and archive of exposure and infection. Several antibody tests have emerged to diagnose SARS-CoV-2. Here we report on a qualified quantitative ELISA assay that displays all the necessary characteristics for high-throughput sample analysis. Collectively, this test offers a quantitative opportunity to define both exposure and levels of immunity to SARS-CoV-2.

引用

页数：12

共 31 条

[1]

Adams E.R., 2020, EVALUATION ANTIBODY, DOI [10.1101/2020.04.15, DOI 10.1101/2020.04.15]

[2]

Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1038/s41591-020-0913-5, 10.1101/2020.03.17.20037713]

[3] SARS-CoV-2 Vaccines: Status Report [J].

Amanat, Fatima ;

Krammer, Florian .

IMMUNITY, 2020, 52 (04) :583-589

[4] Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope [J].

Bajic, Goran ;

Maron, Max J. ;

Adachi, Yu ;

Onodera, Taishi ;

McCarthy, Kevin R. ;

McGee, Charles E. ;

Sempowski, Gregory D. ;

Takahashi, Yoshimasa ;

Kelsoe, Garnett ;

Kuraoka, Masayuki ;

Schmidt, Aaron G. .

CELL HOST & MICROBE, 2019, 25 (06) :827-+

[5]

Bendavid E., 2020, COVID 19 ANTIBODY SE, DOI 10.1101/2020.04.14.20062463

[6] Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses [J].

Chen, Jieliang .

MICROBES AND INFECTION, 2020, 22 (02) :69-71

[7]

Fielding BC, 2011, FUTURE MICROBIOL, V6, P153, DOI [10.2217/fmb.10.166, 10.2217/FMB.10.166]

[8] A previously undescribed coronavirus associated with respiratory disease in humans [J].

Fouchier, RAM ;

Hartwig, NG ;

Bestebroer, TM ;

Niemeyer, B ;

de Jong, JC ;

Simon, JH ;

Osterhaus, ADME .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (16) :6212-6216

[9] Cellular entry of the SARS coronavirus [J].

Hofmann, H ;

Pöhlmann, S .

TRENDS IN MICROBIOLOGY, 2004, 12 (10) :466-472

[10]

Huang Angkana T, 2020, medRxiv, DOI [10.1038/s41467-020-18450-4, 10.1101/2020.04.14.20065771]

← 1 2 3 4 →